Overview
A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer
Status:
Unknown status
Unknown status
Trial end date:
2020-12-30
2020-12-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin（18F-AlF-NOTA-neurotensin）positron emission tomography / computed tomography (PET/CT) in patients with prostate cancer (PCa).Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Xiangya Hospital of Central South University
Criteria
Inclusion Criteria:1. Histologically and/or clinically confirmed and/or suspicious of PCa.
2. Signed informed consent.
Exclusion Criteria:
Claustrophobia (unable to accept PET/CT scanning)